Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010

Preclinical Oncology Developer Secures Polymer Partner to De-Risk ONC010 Manufacturing Ahead of IND Filing

By The Northwire Desk — AI Analysis Jun 23, 2026 · 18:00 ONCO · 0.7 ONCO-INNOVATIONS LIMITED
Executive Summary
  • Onco-Innovations Limited entered into a services agreement with Nanosoft Polymers on June 23, 2026, to advance the development of ONC010, its lead nanoparticle-formulated PNKP inhibitor.
  • Nanosoft will provide polymer process development, analytical characterization, scale-up support, formulation optimization, and technology transfer for Onco's proprietary PEO-PBCL polymer platform.
  • The collaboration aims to strengthen manufacturing and formulation foundations, support IND-enabling activities, and de-risk the pathway toward First-in-Human clinical trials.
  • This agreement follows a non-binding Letter of Intent (LOI) signed on June 5, 2026, and complements ongoing CMC activities with Dalton Pharma Services and preclinical work with Nucro-Technics.
Material Impact
  • The announcement represents standard Chemistry, Manufacturing, and Controls (CMC) progression for a preclinical-stage biotechnology company.
  • It validates manufacturing reproducibility and scalability but does not generate revenue, clinical data, or regulatory approval.
  • The partnership de-risks the long-term development pathway but does not materially alter near-term valuation or cash flow expectations.
  • Given the company's preclinical status and heavy reliance on equity financing, this is an incremental operational milestone rather than a fundamental re-rating event.
ONCO · Price
Company Overview
  • Onco-Innovations is a preclinical-stage biotechnology company developing ONC010, a nanoparticle-formulated PNKP inhibitor intended for difficult-to-treat malignancies.
  • The company operates a wholly-owned subsidiary, Inka Health Corp., which advances the SynoGraph AI-driven precision oncology platform.
  • Development activities are heavily focused on IND-enabling studies, process optimization, and manufacturing scale-up in preparation for First-in-Human clinical trials.
  • Strategic partnerships include Dalton Pharma Services, Nucro-Technics, AstraZeneca, and OneMedNet to support CMC, preclinical, and AI-driven evidence generation.
Read the original news release →

More from ONCO-INNOVATIONS LIMITED

Jun 30, 2026 · 19:00

Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.

Financings Jun 30, 2026 · 18:00

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

M&A / Property Jun 26, 2026 · 18:00

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

Other Jun 26, 2026 · 08:30

Canadian preclinical-stage oncology company developing PNKP inhibitor ONC010 and AI-driven SynoGraph platform.

Other Jun 25, 2026 · 08:30

Preclinical PNKP inhibitor developer burns cash and raises capital while marketing AI oncology partnerships to a niche market.

Other Jun 19, 2026 · 19:00

Onco-Innovations Announces Non-Brokered LIFE Offering

Financings